The convenient, discreet, 3-day, wearable insulin Patch for injection-free dosing
Mealtime Insulin is Always within Reach
Mealtime insulin is always within reach
Simplify Mealtime Insulin With A Click
CeQur Simplicity™ removes known barriers to mealtime dosing,4 such as inconvenience, embarrassment, and injection pain.
- Fits into the lives of people requiring mealtime insulin dosing
- Wearable while showering, sleeping, exercising, and swimming5
- Easy to use
- Worn and dosed under clothing
- Compact design
- Small (65x36 mm), lightweight (10 gm), and thin (<4 quarters thick)
- Less embarrassment while dosing can lead to better adherence1
The 3-day Patch holds up to 200 units of fast-acting insulin administered in 2-unit increments.
CeQur Simplicity Is Designed For Safety
2-Button Safety Mechanism
Ensures that dosing occurs only when intended—designed to prevent accidental dosing5
Designed to keep the Patch on skin for up to 3 days
Buttons Lock To Notify
Stay in “squeezed” position when Patch is empty or cannula is occluded5
To a depth of 1 meter for up to 30 minutes
Tactile & Audible Feedback
Indicates 2-unit delivery5
Users Prefer CeQur Simplicity
CeQur Simplicity Encourages Adherence
Many people using the Patch said that they dosed in instances where they probably wouldn’t have dosed with a pen or syringe, and stated that they are likely to dose more often across meals, snacks, and correction boluses.3
CeQur Simplicity Features
*Labeled for use with Humalog® U-100 and NovoLog® U-100. Insulin sold separately.
- Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with and Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
- Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1)
- Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
- Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
- Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
- Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, LevineB, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603
- Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.
Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.